The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
­Using tumor growth rate to inform treatment efficacy in pancreatic adenocarcinoma: From the metastatic to the neoadjuvant setting.
 
Meredith LaRose
No Relationships to Disclose
 
Celine Yeh
No Relationships to Disclose
 
Mengxi Zhou
No Relationships to Disclose
 
Keith Magnus Sigel
Employment - Oscar Health (I)
Stock and Other Ownership Interests - adial pharmaceuticals (I); Amarin Corporation; Axsome Therapeutics (I); Biohaven Pharmaceuticals (I)
 
Gayle S. Jameson
No Relationships to Disclose
 
Ruth Aroon White
No Relationships to Disclose
 
Rachael A Safyan
Research Funding - Merck (Inst)
 
Yvonne M. Saenger
Research Funding - Regeneron
 
Elizabeth Hecht
No Relationships to Disclose
 
John A. Chabot
Leadership - MORE Health
 
Stephen M. Schreibman
No Relationships to Disclose
 
Antonio Tito Fojo
Honoraria - Merck
Consulting or Advisory Role - Akita Biomedical; ElmediX (I); OnKure (I); PEGASCY (I); SERVIER (I)
Research Funding - Ipsen (Inst); Merck (Inst); Pfizer (I); Pfizer (Inst)
 
Gulam Abbas Manji
Honoraria - Celgene; Cend Therapeutics; Exelixis; Roche/Genentech
Consulting or Advisory Role - Cend Therapeutics; Exelixis; Ipsen; Roche/Genentech
Research Funding - Arcus Biosciences (Inst); BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - AADi; Anthem Inc; CerRx; FORMA Therapeutics; Medtronic; Origin Commercial Advisors; Orpheus Bioscience; Stingray Therapeutics; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Consulting or Advisory Role - Agastiya Biotech; Agenus; AiMed; AlaMab Therapeutics; Alpha Cancer Technologies; Amunix; Aptose Biosciences; Atalion Therapeutics; Athenex; Avesta76 Therapeutics; Axis Therapeutics; BioXCel therapeutics; Bryologyx; CanBas; Caribou Biosciences; Catamaran Bio; Codiak Biosciences; Compass Therapeutics; Coordination Pharmaceuticals; Corcept Therapeutics; CV6 Therapeutics; Cytocom; Decoy Biosystems; DNAtrix; EMD Serono; Erimos Pharmaceuticals; EXACT Therapeutics; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Gimbal; GiraFpharma; GlaxoSmithKline; HUYA Bioscience International; ImaginAb; Imaging Endpoints; Immodulon Therapeutics; ImmuneOncia; Immunophotonics; L.E.A.F. Pharmaceuticals; Lixte Biotechnology; Lycia Therapeutics; NeoTx; NGM Biopharmaceuticals; Nirogy Therapeutics; Novita Pharmaceuticals; Noxxon Pharma; Oncology Venture; Oncolyze; OnQuality Pharmaceuticals; Orphagen Pharmaceuticals; Pfizer; Phosplatin Therapeutics; RadImmune; Reflexion Medical; Reglagene; RenovoRx; Samumed; Seagen; Sellas Life Sciences; Senhwa Biosciences; SignaBlok; Sirnaomics; SonaCare Medical; SOTIO; Sumitomo Dainippon Pharma Oncology; Synergene; TD2; Thirona Biosciences; Tolero Pharmaceuticals; Verily; Vicus Therapeutics; Viracta Therapeutics; Vivacitas Oncology; Xenter; Xerient
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Samumed (Inst); Strategia (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
 
Susan Elaine Bates
Honoraria - Merck (I)
Consulting or Advisory Role - Akita Biomedical (I); ElmediX; Ipsen; OnKure; Pegascy; Progenics (I); Secura Bio (I); SERVIER
Research Funding - Amgen (Inst); Ipsen (Inst); Merck (Inst); Pfizer; Pfizer (Inst); RenovoRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent: Deacetylase Inhibitor Therapy (Inst); Patent: Depsipeptide for Therapy of Kidney Cancer (Inst)